Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers

Background: Evidence of efficacy and safety of programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) checkpoint inhibitors in oesophageal cancer (EC), gastric cancer (GC) and colorectal cancer (CRC) was inconsistent, obscuring their clinical application and decision-making. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Shun-Long, Luo, Jing, Wei, Hua, Qin, Xiao-Li, Jiang, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160363/
https://www.ncbi.nlm.nih.gov/pubmed/37153768
http://dx.doi.org/10.3389/fphar.2023.1106961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10160363/
https://www.ncbi.nlm.nih.gov/pubmed/37153768
http://dx.doi.org/10.3389/fphar.2023.1106961

Ejemplares similares